Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2010 |
| End Date: | December 2012 |
A Phase 1b/2 Study of PCI-32765, a Btk-inhibitor, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Related Diseases
The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily
regimen of orally administered PCI-32765 combined with ofatumumab in subjects with
relapsed/refractory CLL/SLL and related diseases
We found this trial at
1
site
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
Click here to add this to my saved trials
